Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

(2022) Samuel A. Funt et al.   JOURNAL OF CLINICAL ONCOLOGY

Overcoming Chemotherapy Resistance in Germ Cell Tumors

(2022) Zuzana Országhová et al.   Biomedicines

Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer

(2022) Ahmet Murat Aydin et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data

(2022) Daniel D. Joyce et al.   CANCER

TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB

(2022) Ji Xing et al.   Cancers

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration

(2021) Praful Ravi et al.   BJU INTERNATIONAL

Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis

(2021) Matteo Ferro et al.   Frontiers in Oncology

Three versus four cycles of neoadjuvant gemcitabine cisplatin for muscle invasive bladder cancer (MIBC).

(2021) Catherine Kendall Major et al.   JOURNAL OF CLINICAL ONCOLOGY

Four versus Three Cycles of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Implications for Pathologic Response and Survival

(2021) Hiten D. Patel et al.   JOURNAL OF UROLOGY

MP41-11 DEVIATIONS IN CYCLES OF NEOADJUVANT CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER AND IMPLICATIONS FOR PATHOLOGIC RESPONSE AND SURVIVAL

(2021) Enrique Blanco-Martinez et al.   JOURNAL OF UROLOGY

Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer

(2021) David D'Andrea et al.   JOURNAL OF UROLOGY

Comparison of Oncologic Outcomes of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (ddMVAC) with Gemcitabine and Cisplatin (GC) as Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis

(2021) Doo Yong Chung et al.   Cancers

Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen

(2021) Karin Holmsten et al.   Bladder Cancer

Downstaging of muscle invasive bladder cancer using neoadjuvant gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as single-regimens or switch therapy modalities

(2020) Andrew T. Ruplin et al.   Clinical Genitourinary Cancer

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

(2020) Thomas W. Flaig et al.   Journal of the National Comprehensive Cancer Network

Fourier Transform Infrared Spectroscopy as a Cancer Screening and Diagnostic Tool: A Review and Prospects

(2020) Kar-Yan Su et al.   Cancers

European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines

(2020) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Treatment of muscle‐invasive and advanced bladder cancer in 2020

(2020) Vaibhav G. Patel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities

(2020) Gerda de Vries et al.   CANCER TREATMENT REVIEWS

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

(2020) Christian Pfister et al.   EUROPEAN UROLOGY

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

(2020) Renu R Bahadoer et al.   LANCET ONCOLOGY

Clinical predictors and survival outcome of patients receiving suboptimal neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: a single-center experience

(2019) Luca Boeri et al.   WORLD JOURNAL OF UROLOGY

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

(2019) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer

(2018) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy

(2018) Homayoun Zargar et al.   JOURNAL OF UROLOGY

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer

(2018) Charles C. Peyton et al.   JAMA Oncology

Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer

(2018) Di (Maria) Jiang et al.   Clinical Genitourinary Cancer

Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits

(2017) et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

(2017) Sam S. Chang et al.   JOURNAL OF UROLOGY

Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study

(2016) Nobuyuki Hinata et al.   BJU INTERNATIONAL

Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy

(2016) Jinbo Chen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis

(2016) Ming Yin et al.   ONCOLOGIST

The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy

(2016) William P. Parker et al.   WORLD JOURNAL OF UROLOGY

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer

(2015) Matthew D. Galsky et al.   CANCER

Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

(2015) Homayoun Zargar et al.   EUROPEAN UROLOGY

Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes

(2015) Nilay M. Gandhi et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin

(2015) Elisabeth E. Fransen van de Putte et al.   WORLD JOURNAL OF UROLOGY

Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Invasive Transitional and Squamous Cell Carcinoma of the Bladder: Effect on Survival and Bladder Preservation

(2014) Hussein M. Khaled et al.   Clinical Genitourinary Cancer

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses

(2013) W.G. Melsen et al.   CLINICAL MICROBIOLOGY AND INFECTION

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

(2012) Nobuaki Matsubara et al.   Asia-Pacific Journal of Clinical Oncology

Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer

(2011) Robert Rosenblatt et al.   EUROPEAN UROLOGY

Neoadjuvant Gemcitabine Plus Cisplatin for Muscle-invasive Bladder Cancer

(2011) G. Kaneko et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

(2011)   JOURNAL OF CLINICAL ONCOLOGY

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy

(2009) Nicholas J. Hellenthal et al.   BJU INTERNATIONAL